Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone plus Fruquintinib in Platinum-Resistant Ovarian Cancer
NCT06973421Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and fruquintinib in ovarian cancer, sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
utidelonefruquintinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06973421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973421.